Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT02428582
Other study ID # MEC-2013-476
Secondary ID
Status Active, not recruiting
Phase N/A
First received
Last updated
Start date May 2016
Est. completion date November 2021

Study information

Verified date March 2021
Source Erasmus Medical Center
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

To compare the outcome of revascularisation the gastrointestinal arteries using covered stents compared to bare-metal stents in patients with CGI.


Description:

Symptomatic chronic atherosclerotic gastrointestinal ischemia (CGI) is an uncommon, potentially underdiagnosed condition caused by fixed stenosis or occlusion of in most conditions at least one of the three gastrointestinal arteries. Atherosclerosis is a predisposing factor for CGI. Clinical symptoms can vary widely. Typical symptoms are postprandial abdominal pain, unintended weight loss and food avoidance. But atypical abdominal pain such as exercise related pain, diarrhoea and nausea can also indicate CGI. The use of endovascular techniques for revascularization of chronic stenosis and occlusions of the gastrointestinal arteries has rapidly increased and endovascular therapy with stenting has become the most common method chosen for revascularization, having replaced open surgery with its associated morbidity and mortality. Nowadays standard care in significant chronic gastrointestinal ischemia is the use of bare metal stents although the patency of these stents is not very high. According retrospective data the patency of covered stents is significantly higher compared to bare metal stents. One likely explanation for these lower restenosis and re-intervention rates observed with covered stents is the established barrier to tissue ingrowth. Only recent retrospective data about this topic is available but the expectancy in this prospective study is that the patency of covered stents is indeed higher compared to metal stents.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 84
Est. completion date November 2021
Est. primary completion date November 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Patients with consensus diagnostic of CGI based on a clinical meeting with a gastroenterologist, a vascular surgeon and an interventional radiologist. - Diagnostic consensus of CGI is based on. - Presence of postprandial pain - Unexplained weight loss (>5% of normal body weight). - Significant stenosis of >50% of at least one of the gastrointestinal arteries on a recent CTA (Computer Tomographic Angiography) not older than one year, with maximum slice thickness 1 mm and enhancement in aorta of 300HU (Hounsfields Units) - Mucosal ischemia detected by VLS (Visible Light Spectroscopy) or tonometry - Patients over the age of 18 years. - Patients who gave informed consent. - Patients have sustained atherosclerosis. Exclusion Criteria: - Patients who don't give informed consent. - Age < 18 years - No stenosis detected during arteriography. - Renal insufficiency (GFR below 30 ml/min or GFR below 60 ml/min when comorbidities relevant to kidney function present). - Previous stent placement in the to be treated gastrointestinal artery. - Pregnancy - Celiac artery compression syndrome. - Vasculitis

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Covered stent (Atrium Type V12)
An endovascular treatment that consists of inserting a covered stent into the stenosed vessels.
Bare stent (Brand Cordis Type Palmaz Blue)
An endovascular treatment that consists of inserting a stent into the stenosed vessels.

Locations

Country Name City State
Netherlands ErasmusMC Rotterdam Zuid Holland

Sponsors (1)

Lead Sponsor Collaborator
Erasmus Medical Center

Country where clinical trial is conducted

Netherlands, 

Outcome

Type Measure Description Time frame Safety issue
Primary The difference of primary and secondary patency rates of covered stents versus bare-metal stents to treat atherosclerotic CGI disease. 12 to 24 months
Secondary The freedom from restenosis after 6-, 12- and 24- months after stent implantation Restenosis is defined as >50% intra-stent stenosis regardless of whether the patient has clinical symptoms 6 to 24 month
Secondary The freedom from symptom recurrence after 6-, 12- and 24- months after stent implantation Symptom recurrence is defined as occurrence of clinical symptoms typical for CGI regardless of stent patency 6 to 24 month
Secondary The freedom from reintervention after 6-, 12- and 24- months after stent implantation Re-intervention is defined as intervention due to symptom occurrence in the presence of >50% intra -stenosis, either a reimplantation of stent or a surgical procedure. 6 to 24 month
Secondary The clinical outcome in terms of quality of life and therapeutic and total costs after 6-, 12- and 24- months after stent implantation 6 to 24 month
Secondary The clinical outcome in terms therapeutic and total costs after 6-, 12- and 24- months after stent implantation 6 to 24 month
See also
  Status Clinical Trial Phase
Not yet recruiting NCT06032572 - Evaluation of the Safety and Effectiveness of the VRS100 System in PCI (ESSENCE) N/A
Not yet recruiting NCT02866656 - The Clinical Research of Low Intensity Continuous Ultrasonic on Lower Limb Arteriosclerosis Occlusion(ASO) Syndrome N/A
Completed NCT02510547 - Comparison of a CrossBoss First Versus Standard Wire Escalation Strategy for Crossing Coronary Chronic Total Occlusion: the "CrossBoss First" Trial Phase 4
Completed NCT02264717 - Dan-NICAD - Danish Study of Non-Invasive Diagnostic Testing in Coronary Artery Disease N/A
Completed NCT01334268 - RESOLUTE China RCT N/A
Active, not recruiting NCT00154180 - Kronos Early Estrogen Prevention Study (KEEPS) Phase 4
Recruiting NCT04343209 - Ammonia N-13 Myocardial Blood Flow Absolute Quantification by PET in Patients With Known or Suspected CAD (Ammonia MAP)
Not yet recruiting NCT06039748 - Angiography-Derived Quantitative Functional Assessment Versus Pressure-Derived FFR and IMR: The FAIR Study
Recruiting NCT04142021 - Safety and Feasibility Evaluation of Planning and Execution of Surgical Revascularization Solely Based on Coronary CTA and FFRCT in Patients With Complex Coronary Artery Disease (FASTTRACK CABG)
Recruiting NCT06008756 - MK-0616 (Oral PCSK9 Inhibitor) Cardiovascular Outcomes Study (MK-0616-015) CORALreef Outcomes Phase 3
Completed NCT03253692 - Prospective Multicenter Registry On Radiation Dose Estimates Of Cardiac CT Angiography in Daily Practice in 2017 (PROTECTION VI)
Active, not recruiting NCT04624854 - Dual Anti-Platelet Therapy in Patients With Coronary Multi-Vessel Disease (DAPT-MVD) Phase 4
Active, not recruiting NCT02921230 - Trial Comparing ELUVIA Versus Bare Metal Stent in Treatment of Superficial Femoral and/or Proximal Popliteal Artery N/A
Recruiting NCT01774058 - The Arterial Measurement of the Blood Flow Volume After Iloprost Stimulation Phase 2
Terminated NCT01462721 - The eSVS® Mesh Randomized Post-Market Study N/A
Completed NCT01455974 - The Effects of Lowering Dialysate Sodium in Hypertensive Hemodialysis Patients N/A
Completed NCT01221610 - BIOLUX P-I First in Man Study N/A
Active, not recruiting NCT00863967 - Early Detection of Arteriosclerosis N/A
Active, not recruiting NCT00174902 - The Effect of Beta-Blockers and Aspirin on Hemostasis and Endothelial Function After Acute Mental Stress Phase 1/Phase 2
Completed NCT00050817 - Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management and Avoidance (CHARISMA) Phase 3